Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU
Department of Clinical and Molecular Medicine, NTNU

INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)
INA-6 (human multiple myeloma cell line)

treated with 10 μM melphalan for 6 hours
treated with 10 μM melphalan and 2 μM NG25 for 6 hours